The ubiquitin–proteasome system (UPS) has links to numerous diseases, and the clinical success of proteasome inhibitors suggests the potential to develop drugs targeting other components of the UPS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback